Jazz Pharmaceuticals has an unwavering commitment to improving care for patients with serious medical conditions through innovative treatments. We are working to expand our current portfolio of commercial products through targeted investments in post-discovery research and development. We are working closely with healthcare professionals and patient advocates to identify significant treatment gaps where Jazz Pharmaceuticals’ approach to patient care may be able to help solve problems in a unique way that will make a substantive difference for patients.

Our long-term vision includes building a development pipeline that could offer potential new treatment options for patients. Our current research and development efforts include programs to improve the current products in our oncology and psychiatry franchises, as well as other development opportunities that support our mission to improve patient’s lives.



(asparaginase Erwinia

  • IV formulation in development
  • Exploring additional labeling opportunities



  • Anti-CD25 monoclonal antibody
  • Treatment of steroid-refractory acute graft vs. host disease
  • EU Phase III study underway



  • Pegylated recombinant erwinia asparaginase
  • E. Coli asparaginase hypersensitivity
  • Currently in Phase I development in EU